战略与国际研究中心-Global-Health-Interventions-for-US-Food-and-Drug-Safety_23页_494kb

Summary of "Global Health Interventions for U.S. Food and Drug Safety"

Core Content

This report, authored by Thomas J. Bollyky and published by the CSIS Global Health Policy Center in November 2009, discusses the growing challenges the United States faces in ensuring the safety of food and drug imports in an increasingly globalized world. It argues that traditional methods of U.S. regulatory oversight at borders are insufficient due to the scale, complexity, and international nature of the global food and drug supply chain. The report emphasizes the need for a more integrated, global approach to food and drug safety that involves collaboration with foreign governments, international institutions, and the private sector.

Main Points and Recommendations

Main Points

1. Globalization of Food and Drug Trade

   • The global food and drug trade has expanded significantly, with U.S. food imports growing from $38 billion in 2000 to $80 billion in 2008.
   • A large portion of U.S. food and drug imports come from developing countries with less-developed regulatory systems.

2. Limitations of U.S. Regulatory Capacity

   • U.S. regulators face legal and practical constraints in conducting extraterritorial inspections.
   • The cost of inspecting all foreign facilities is prohibitively high, and the volume of imports makes comprehensive border inspections infeasible.

3. Complex Supply Chains

   • Food and drug products are often made from components sourced across multiple countries, making it difficult to trace and ensure safety.
   • Contamination or substandard practices in one part of the supply chain can compromise the safety of the final product.

4. Incoherence in Global Standards

   • There is a lack of coherence in international, national, and private food and drug standards, leading to inconsistent enforcement and compliance challenges.

5. Case Study: Heparin Crisis

   • The 2008 heparin contamination crisis highlighted the difficulty of identifying and preventing unsafe imports, as the contamination originated in China and was not detected until it reached the U.S. market.
   • The crisis led to significant public health consequences, legal actions, and reputational damage for U.S. companies and Chinese exporters.

6. Current U.S. Initiatives

   • The U.S. has launched several initiatives, including the Import Safety Action Plan (2007) and the Beyond Our Borders Initiative (2008), to improve global food and drug safety.
   • However, these initiatives lack detailed strategies for building regulatory capacity in developing countries and improving international cooperation.

Recommendations

• Shift Inspection Focus to Origin Countries

  • Inspection and quality control of food and drug products should occur closer to their place of origin, not just at U.S. borders.
  • U.S. border surveillance should complement, not replace, local regulatory efforts.

• Increase Resources for Developing Countries

  • More funding and support should be directed toward developing countries to strengthen their regulatory systems.
  • Resources should be prioritized based on the volume and risk of imports to the U.S.

• Promote International Cooperation

  • The U.S. must engage with the broader global health safety agenda and work with developing country exporters.
  • A combination of incentives (carrots) and enforcement (sticks) should be used to encourage compliance with U.S. safety standards.

• Enhance Regulatory Interoperability

  • Efforts to build local regulatory capacity should be coordinated regionally and internationally.
  • The U.S. should integrate food and drug safety into its international trade and economic policies.

• Support Multilateral Institutions

  • The U.S. should support global initiatives that promote regulator interoperability, information exchange, and cooperation.

Key Information

• U.S. Public Health Concern: 67% of Americans are worried about food safety, according to a 2008 poll.
• FDA and FSIS Responsibilities: The FDA regulates 80% of the U.S. food supply, while the FSIS oversees meat, poultry, and processed egg products.
• Import Inspection Challenges: The FDA had only 450 port inspectors in 2008, examining just 1% of food imports.
• Cost of Inspections: A 2008 GAO report estimated that inspecting all 189,000 foreign food facilities would cost approximately $3.16 billion.
• Heparin Case: The 2008 heparin contamination crisis involved substitution of a cheaper chemical for genuine heparin, resulting in 19 U.S. deaths and 365 worldwide.
• U.S. Spending on Capacity Building: In 2008, the U.S. obligated $6.6 million for SPS trade capacity building, which is the lowest since 2000. The FDA's support for such efforts is also limited compared to the USDA.

Conclusion

The report concludes that food and drug safety are global health issues that require a coordinated, multilateral approach. While the U.S. has taken steps to improve its oversight, more needs to be done to build regulatory capacity abroad, enhance international cooperation, and harmonize standards. Without these efforts, the U.S. will continue to face challenges in ensuring the safety of its food and drug imports.